MAP3K12

Across TCGA pan-cancer cohorts, MAP3K12 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of MAP3K12’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where MAP3K12 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAP3K12 is over-expressed in tumor, although a few such as UCEC and KICH show the opposite, repressed pattern.

KIRP, KIRC, and HNSC are the cancer types where MAP3K12 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP3K12 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	IV	+1.617	<.001	11	view →
KIRC	Male	IV	+0.823	<.001	11	view →
HNSC	All	III,IV	+0.526	<.001	10	view →
LIHC	Female	All	+0.564	<.001	7	view →
UCEC	All	All	−1.162	<.001	6	view →
KICH	Female	All	−1.018	<.001	4	view →
LUSC	All	All	−0.502	<.001	4	view →
CHOL	Female	All	+2.130	<.001	3	view →
LUAD	All	All	−0.274	.015	3	view →
PRAD	All	All	−0.477	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

MAP3K12–KIRP

Open the KIRP breakdown →